Cenisertib Inhibitor

Name: Cenisertib Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754696
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754696

Cenisertib (AS-703569) is a multi-kinase inhibitor and blocks the activity of Aurora-kinase-A/B, AKT, ABL1, STAT5, and FLT3. Cenisertib inhibits tumor growth in xenograft models of breast, pancreatic, ovarian, colon, lung tumors, and leukemia. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Cenisertib, Inhibitor

Full Product Name

Cenisertib

Product Synonym Names

AS-703569; R-763

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

451.54

Solubility

DMSO: 250mg/mL (553.66mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C24H30FN7O

SMILES

[H][C@@]1([C@H]([C@H]2C(N)=O)NC3=NC(NC4=CC=C(C(C)=C4)N5CCN(CC5)C)=NC=C3F)C[C@]2(C=C1)[H]

CAS Number

871357-89-0

Target & IC50

Aurora-A
Aurora-B
ABL1
Akt
STAT5

In Vitro

Cenisertib (p.o.; 7 or 10mg/kg/day; for 3 days) evidently suppresses tumor growth [2].

Product Categories/Family for Cenisertib, inhibitor

Angiogenesis; Bcr-Abl; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; JAK/STAT signaling; Stem Cells

Product References and Citations for Cenisertib, inhibitor

Peter B, et al. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018 Apr;32(4):1016-1022.
Peter B, et al. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018 Apr;32(4):1016-1022.
McLaughlin J, et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.
McLaughlin J, et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.

Other Notes

Small volumes of Cenisertib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Cenisertib purchase

MBS5754696 is an inhibitor targeting Cenisertib.